Bradykinin and renal fibrosis: Have we ACE'd it?

Journal of the American Society of Nephrology

Volumn 15, Issue 9, 2004, Pages 2504-2506

  Bascands, Jean Loup ^a   Schanstra, Joost P ^a  

^a CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MATRIX METALLOPROTEINASE; PLASMINOGEN;

DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; EDITORIAL; EXTRACELLULAR MATRIX; HUMAN; KIDNEY FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING;

EID: 4344614887     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000143721.71748.30     Document Type: Editorial

References (33)

1. U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2003
2. Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 318: 1657-1666, 1988
3. Owen WF Jr: Patterns of care for patients with chronic kidney disease in the United States: dying for improvement. J Am Soc Nephrol 14 [Suppl 2]: S76-80, 2003
4. Nath KA: Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1: 1-17, 1992
5. Okada H, Watanabe Y, Kikuta T, Kobayashi T, Kanno Y, Sugaya T, Suzuki H: Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstium under angiotensin converting enzyme blockade. J Am Soc Nephrol 15: 2404-2413, 2004
6. Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP:Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 58: 1841-1850, 2000
7. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA: PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60: 587-596, 2001
8. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA: A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomeru-lonephritis. J Clin Invest 112: 379-388, 2003
9. Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, Nejak K, Liu Y: Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 110: 1525-1538, 2002
10. Edgtton KL, Gow RM, Kelly DJ, Carmeliet P, Kitching AR: Plasmin is not protective in experimental renal interstitial fibrosis. Kidney Int 66: 68-76, 2004
11. Ingelfinger JR: Forestalling fibrosis. N Engl J Med 349: 2265-2266, 2003
12. Fogo AB: Renal fibrosis: not just PAI-1 in the sky. J Clin Invest 112: 326-328, 2003
13. Hertig A, Rondeau E: Plasminogen activator inhibitor type 1: the two faces of the same coin. Curr Opin Nephrol Hypertens 13: 39-44, 2004
14. Eddy AA: Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290-301, 2000
15. Iwano M, Neilson EG: Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 13: 279-284, 2004
16. Liu Y: Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15: 1-12, 2004
17. Strutz F: Potential methods to prevent interstitial fibrosis in renal disease. Expert Opin Investig Drugs 10: 1989-2001, 2000
18. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993
19. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354: 359-364, 1999
20. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH: Renoprotection: one or many therapies? Kidney Int 59: 1211-1226, 2001
21. Jaspard E, Wei L, Alhenc-Gelas F: Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 268: 9496-9503, 1993
22. Campbell DJ, Kladis A, Duncan AM: Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23: 439-449, 1994
23. Duncan AM, Kladis A, Jennings GL, Dart AM, Esler M, Campbell DJ: Kinins in humans. Am J Physiol Regul Integr Comp Physiol 278: R897-904, 2000
24. Remme WJ: Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy? Drugs 54 [Suppl 5]: 59-70, 1997
25. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ: Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339: 1285-1292, 1998
26. Heart Outcomes Prevention Evaluation (HOPE) study investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259, 2000
27. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial- the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582-1587, 2000
28. Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE: Bradykinin contributes to the vasodilator effects of chronic angio-tensin-converting enzyme inhibition in patients with heart failure. Circulation 104: 2177-2181, 2001
29. Silva JA Jr, Araujo RC, Baltatu O, Oliveira SM, Tschope C, Fink E, Hoffmann S, Plehm R, Chai KX, Chao L, Chao J, Ganten D, Pesquero JB, Bader M: Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J 14: 1858-1860, 2000
30. Schanstra JP, Neau E, Drogoz P, Arevalo Gomez MA, Lopez Novoa JM, Calise D, Pecher C, Bader M, Girolami JP, Bascands JL: In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 110: 371-379, 2002
31. Nabokov A, Amann K, Gassmann P, Schwarz U, Orth SR, Ritz E: The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity. Nephrol Dial Transplant 13: 173-176, 1998
32. Schanstra JP, Duchene J, Desmond L, Neau E, Calise D, Estaque S, Girolami JP, Bascands JL: The protective effect of angiotensin converting enzyme inhibition in experimental renal fibrosis in mice is not mediated by bradykinin B2 receptor activation. Thromb Haemost 89: 735-740, 2003
33. Zheng G, Haris DCH: Plasmin in renal interstitial fibrosis: innocent or guilty? Kidney Int 66: 455-456, 2004